FDA Grants Fast Track Designation to Zotiraciclib for IDH-Mutant Recurrent High-Grade Glioma
核心洞察
The FDA has granted Fast Track Designation to Cothera Bioscience (搜索)'s zotiraciclib for treating patients with recurrent high-grade gliomas harboring IDH1 (搜索) or IDH2 (搜索) mutations.
Zotiraciclib is a potent, oral, brain-penetrant multi-kinase inhibitor that primarily targets CDK9 (搜索) and creates synthetic-lethal vulnerability in IDH-mutant gliomas (搜索).
The designation was supported by successful completion of a Phase I clinical trial sponsored by the National Cancer Institute demonstrating safety and preliminary efficacy.
The U.S. Food and Drug Administration has granted Fast Track Designation to zotiraciclib (ZTR/TG02) for the treatment of patients with recurrent high-grade gliomas (rHGG) harboring IDH1 (搜索) or IDH2 (搜索) mutations, Cothera Bioscience (搜索) announced. This designation provides an expedited regulatory pathway to accelerate the development and review of the investigational therapy for these aggressive brain tumors (搜索) that have no established standard of care, limited treatment options, and poor prognoses.
Novel Mechanism Targets Previously Undruggable Pathway
Zotiraciclib is a potent, oral, brain-penetrant multi-kinase inhibitor that primarily targets CDK9 (搜索). The drug suppresses the transcription of short-lived anti-apoptotic proteins, disrupting tumor cell survival. Additionally, zotiraciclib impairs mitochondrial function and suppresses stress-response pathways, creating a synthetic-lethal vulnerability in IDH-mutant gliomas (搜索).
This dual mechanism supports zotiraciclib as a monotherapy option for IDH-mutant recurrent high-grade glioma (搜索), potentially eliminating the need for combination with cytotoxic chemotherapies and improving quality of life for patients.
Clinical Evidence Supports FDA Decision
The FDA's decision was supported by the successful completion of a Phase I clinical trial sponsored by the National Cancer Institute, part of the National Institutes of Health, which demonstrated the safety and preliminary efficacy of zotiraciclib as a single-agent therapy for patients with IDH-mutant recurrent high-grade glioma (搜索) (NCT05588141).
Results from this study were presented on November 22-23, 2025, at the 2025 WFNOS and SNO Annual Meeting in Honolulu, Hawaii, in a presentation titled "Phase I/II study of zotiraciclib for recurrent malignant gliomas with IDH mutations: results of the phase I study."
Addressing Critical Unmet Medical Need
"Receiving US FDA Fast Track Designation for zotiraciclib marks a pivotal moment in our mission to improve outcomes for patients with IDHmut rHGG," said Vernon Jiang of R&D at Cothera Bioscience (搜索). "This designation accelerates our efforts to deliver the first breakthrough targeted therapy for this patient population since the approval of temozolomide in 1999."
Dr. Jing Wu, Acting Deputy Chief of the Neuro-Oncology Branch at NCI and Principal Investigator of the ongoing Phase I/II study, emphasized the significance of the clinical data. "We are grateful to the patients and families who participated in these studies, as well as to our clinical and research teams at the NCI," Wu said. "The monotherapy study data gathered to date provide important insights into the safety and biological activity of zotiraciclib. We remain committed to advancing zotiraciclib into subsequent phases of development with the goal of bringing a new therapeutic option to patients with IDH-mutant recurrent high-grade gliomas."
Next Steps in Development
Cothera Bioscience (搜索) will continue to work closely with the FDA and its clinical partners to advance the development of zotiraciclib, including the initiation of additional clinical studies and preparation for regulatory submissions. The Fast Track Designation highlights the urgent need for new therapeutic approaches in this devastating brain cancer with high unmet medical needs.